Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

AEON Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- EXECUTED A $15.3 MILLION FINANCING WITH MILESTONE WARRANTS PROVIDING POTENTIAL FOR AN ADDITIONAL $34.0 MILLION IN GROSS PROCEEDS, SUPPORTING CONTINUED ADVANCEMENT OF ABP-450'S DEVELOPMENT PROGRAM

AEON BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

ALISO VIEJO, CALIF., AUG. 03, 2026 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY ADVANCING ABP-450 AS A BIOSIMILAR TO BOTOX (ONABOTULINUMTOXINA) FOR THERAPEUTIC USE TO ACHIEVE FULL-LABEL U.S. MARKET ENTRY, TODAY ANNOUNCED THAT IT HAS RECEIVED WRITTEN NOTICE FROM NYSE AMERICAN LLC (NYSE AMERICAN) CONFIRMING THAT AEON HAS REGAINED COMPLIANCE WITH NYSE AMERICAN'S CONTINUED LISTING STANDARDS RELATING TO STOCKHOLDERS' EQUITY.

AEON BIOPHARMA REGAINS COMPLIANCE WITH NYSE AMERICAN CONTINUED LISTING STANDARDS

VICTORIA, SEYCHELLES, JULY 27, 2026 (GLOBE NEWSWIRE) -- BITGET , THE WORLD'S LARGEST UNIVERSAL EXCHANGE (UEX), ANNOUNCED THE ADDITION OF AEON (AEON) TO BITGET LAUNCHPOOL AND SPOT MARKET. SPOT TRADING FOR THE AEON/USDT PAIR OPENS ON JULY 27, 2026, 11:00 (UTC), WITH WITHDRAWALS AVAILABLE FROM JULY 28, 2026, 12:00 (UTC).

BITGET LAUNCHPOOL ADDS AEON (AEON) WITH 1.1M IN TOKEN REWARDS

$13.75 MILLION UNDERWRITTEN PUBLIC OFFERING WITH UP TO AN ADDITIONAL $29.6 MILLION IN POTENTIAL PROCEEDS TIED TO THE CASH EXERCISE IN FULL OF THE MILESTONE WARRANTS ISSUED IN THE OFFERING $13.75 MILLION UNDERWRITTEN PUBLIC OFFERING WITH UP TO AN ADDITIONAL $29.6 MILLION IN POTENTIAL PROCEEDS TIED TO THE CASH EXERCISE IN FULL OF THE MILESTONE WARRANTS ISSUED IN THE OFFERING

AEON BIOPHARMA ANNOUNCES PRICING OF UPSIZED $13.75 MILLION PUBLIC OFFERING WITH ACCOMPANYING MILESTONE WARRANTS PROVIDING POTENTIAL FOR ADDITIONAL FUTURE FUNDING

IRVINE, CALIF., JUNE 04, 2026 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY ADVANCING ABP-450 AS A BIOSIMILAR TO BOTOX (ONABOTULINUMTOXINA) FOR THERAPEUTIC USE TO ACHIEVE FULL-LABEL U.S. MARKET ENTRY, TODAY ANNOUNCED THE PRESENTATION OF NEW ANALYTICAL AND FUNCTIONAL DATA SUPPORTING BIOSIMILARITY OF ABP-450 TO BOTOX AT THE 68TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN HEADACHE SOCIETY (AHS), BEING HELD JUNE 4-7, 2026 IN ORLANDO, FLORIDA. THE POSTER IS BEING PRESENTED BY CHAD K. OH, M.D., AEON'S CHIEF MEDICAL OFFICER.

AEON BIOPHARMA TO PRESENT DATA DEMONSTRATING STRUCTURAL AND FUNCTIONAL COMPARABILITY OF ABP-450 TO BOTOX AT THE 68TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN HEADACHE SOCIETY

- REPORTED POSITIVE FDA TYPE 2A MEETING SUPPORTING ABP-450'S COMPARATIVE ANALYTICAL STRATEGY UNDER THE 351(K) REGULATORY PATHWAY - - STRENGTHENED BALANCE SHEET THROUGH FINANCING TRANSACTIONS AND DAEWOONG NOTE EXCHANGE, REDUCING OUTSTANDING DEBT BY MORE THAN 90% - - BOLSTERED LEADERSHIP TEAM WITH APPOINTMENT OF JOHN BENCICH AS CHIEF FINANCIAL OFFICER - IRVINE, CALIF., MAY 14, 2026 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY ADVANCING ABP-450 AS A BIOSIMILAR TO BOTOX (ONABOTULINUMTOXINA) FOR THERAPEUTIC USE TO ACHIEVE FULL-LABEL U.S. MARKET ENTRY, REPORTED TODAY ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE.

AEON BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- ANNUAL SHAREHOLDER MEETING TO BE HELD AT 10:00 AM PT ON JUNE 17, 2026 - IRVINE, CALIF., APRIL 24, 2026 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY ADVANCING ABP-450 (PRABOTULINUMTOXINA) AS A BIOSIMILAR TO BOTOX (ONABOTULINUMTOXINA) TO ACHIEVE FULL-LABEL U.S. MARKET ENTRY, TODAY ANNOUNCED THAT ITS ANNUAL SHAREHOLDER MEETING WILL BE HELD AT 10:00 AM PACIFIC TIME (PT) ON WEDNESDAY, JUNE 17, 2026 AND WILL BE HELD IN THE COMPANY'S OFFICES AT 5 PARK PLAZA, SUITE 1750, IRVINE, CA 92614.

AEON BIOPHARMA SETS ANNUAL SHAREHOLDER MEETING

IRVINE, CALIF., APRIL 03, 2026 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY ADVANCING ABP-450 (PRABOTULINUMTOXINA) AS A BIOSIMILAR TO BOTOX (ONABOTULINUMTOXINA) TO ACHIEVE FULL-LABEL U.S. MARKET ENTRY, TODAY ANNOUNCED THAT, ON APRIL 2, 2026, IN CONNECTION WITH THE APPOINTMENT OF JOHN BENCICH AS CHIEF FINANCIAL OFFICER, THE COMPANY'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) APPROVED THE GRANT OF INDUCEMENT AWARDS.

AEON BIOPHARMA REPORTS INDUCEMENT GRANTS UNDER NYSE AMERICAN LLC COMPANY GUIDE SECTION 711

IRVINE, CALIF., APRIL 03, 2026 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY ADVANCING ABP-450 (PRABOTULINUMTOXINA) AS A BIOSIMILAR TO BOTOX (ONABOTULINUMTOXINA) TO ACHIEVE FULL-LABEL U.S. MARKET ENTRY, TODAY ANNOUNCED THAT ON MARCH 31, 2026, IT RECEIVED A NOTICE (THE NOTICE) FROM NYSE AMERICAN LLC (NYSE AMERICAN) INDICATING THAT, FOLLOWING ITS YEAR-END FINANCIAL RESULTS, THE COMPANY IS NOT IN COMPLIANCE WITH AN ADDITIONAL CONTINUED LISTING STANDARD SET FORTH IN THE NYSE AMERICAN COMPANY GUIDE (THE COMPANY GUIDE).

AEON BIOPHARMA RECEIVES ADDITIONAL NOTICE RELATED TO NYSE AMERICAN CONTINUED LISTING STANDARDS

AEON BIOPHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND HIGHLIGHTS POSITIVE COMPARATIVE ANALYTICAL RESULTS AND FDA FEEDBACK FOR ABP-450 BIOSIMILAR PROG

AEON BIOPHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND HIGHLIGHTS POSITIVE COMPARATIVE ANALYTICAL RESULTS AND FDA FEEDBACK FOR ABP-450 BIOSIMILAR PROGRAM

AEON Biopharma, Inc.

AEON

Price

Financial Reports

No items found.

Press Releases

AEON Biopharma, Inc.

AEON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AEON